Form 4: Sutro Biopharma CEO William Newell Reports Stock Option Grant and RSU Vesting
SEC Form 4 Filing
CEO William Newell reports acquisition and disposal of Sutro Biopharma stock and derivative securities, including stock options and restricted stock units (RSUs), through vesting and tax withholding.
Summary
- On March 5, 2024, William J. Newell, CEO of Sutro Biopharma, engaged in transactions involving the company's stock and derivative securities.
- Newell acquired 18,750 shares of common stock through the exercise of restricted stock units (RSUs).
- He also disposed of 6,690 shares to cover income tax withholding obligations related to the RSU settlement.
- Following these transactions, Newell directly owns 220,203 shares of common stock and indirectly owns 116,525 shares through the William J. Newell Family Trust.
- Newell was granted options to purchase 174,000 shares of common stock at an exercise price of $4.54, vesting monthly from April 1, 2024, and fully vested by March 1, 2028.
- He also acquired 130,500 RSUs, vesting annually from March 1, 2025.
- Additionally, 18,750 RSUs vested on March 5, 2024, as part of an earlier grant.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the document primarily reports routine insider transactions related to equity compensation. There are no explicit positive or negative implications for the company's performance.
Positives
- The vesting of RSUs and stock options suggests Newell's continued commitment to Sutro Biopharma.
- The acquisition of shares through RSU vesting increases Newell's direct ownership in the company.
Negatives
- The disposal of shares to cover tax obligations, while standard, slightly reduces Newell's direct holdings.
Risks
- There are no specific risks highlighted in this document, as it primarily reports transactions related to equity compensation.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and RSUs suggest a continued relationship between Newell and Sutro Biopharma.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors regarding the holdings and transactions of company executives.
Comparison to Industry Standards
- Equity compensation, including stock options and RSUs, is a common practice in the biotechnology industry to incentivize and retain key executives.
- Vesting schedules and terms are generally aligned with industry norms to ensure long-term commitment and alignment with shareholder interests.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity compensation strategies for their executives.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
- The vesting of equity awards incentivizes the CEO to continue driving company performance, which benefits shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/15/2019 | Date of the William J. Newell Family Trust. |
| 03/05/2024 | Date of the reported transactions, including RSU vesting, stock disposal for tax withholding, and option grant. |
| 03/07/2024 | Date of the form's signature. |
| 04/01/2024 | Start date for monthly vesting of stock options. |
| 03/01/2025 | Start date for annual vesting of RSUs. |
| 03/01/2028 | Date when 100% of the stock options will be vested and exercisable. |
| 03/05/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.